Aliases & Classifications for Dysautonomia

MalaCards integrated aliases for Dysautonomia:

Name: Dysautonomia 50 28 51 69

Classifications:



External Ids:

UMLS 69 C0013363

Summaries for Dysautonomia

NINDS : 50 Dysautonomia refers to a disorder of autonomic nervous system (ANS) function that generally involves failure of the sympathetic or parasympathetic components of the ANS, but dysautonomia involving excessive or overactive ANS actions also can occur. Dysautonomia can be local, as in reflex sympathetic dystrophy, or generalized, as in pure autonomic failure. It can be acute and reversible, as in Guillain-Barre syndrome, or chronic and progressive. Several common conditions such as diabetes and alcoholism can include dysautonomia. Dysautonomia also can occur as a primary condition or in association with degenerative neurological diseases such as Parkinson's disease. Other diseases with generalized, primary dysautonomia include multiple system atrophy and familial dysautonomia. Hallmarks of generalized dysautonomia due to sympathetic failure are impotence (in men) and a fall in blood pressure during standing (orthostatic hypotension). Excessive sympathetic activity can present as hypertension or a rapid pulse rate.

MalaCards based summary : Dysautonomia is related to neuropathy, hereditary sensory and autonomic, type iii and parkinson disease, late-onset. An important gene associated with Dysautonomia is ELP1 (Elongator Complex Protein 1), and among its related pathways/superpathways are Chks in Checkpoint Regulation and Neuroscience. The drugs Dopamine and Metoprolol have been mentioned in the context of this disorder. Affiliated tissues include heart, spinal cord and brain, and related phenotypes are Decreased telomerase activity and no phenotypic analysis

Wikipedia : 72 Dysautonomia or autonomic dysfunction is a condition in which the autonomic nervous system (ANS) does... more...

Related Diseases for Dysautonomia

Diseases in the Dysautonomia family:

Dysautonomia-Like Disorder

Diseases related to Dysautonomia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 206)
# Related Disease Score Top Affiliating Genes
1 neuropathy, hereditary sensory and autonomic, type iii 33.0 ACTL7B ELP1 LIFR
2 parkinson disease, late-onset 31.0 PRKN SNCA SNCAIP
3 autonomic neuropathy 29.8 ELP1 NTRK1
4 multiple system atrophy 1 29.7 PRKN SNCA
5 supranuclear palsy, progressive, 1 29.1 PRKN SNCA
6 synucleinopathy 28.9 PRKN SNCA SNCAIP
7 dementia 28.9 PRKN SNCA SNCAIP
8 dysautonomia-like disorder 12.1
9 motor neuropathy, peripheral, with dysautonomia 12.0
10 acute cholinergic dysautonomia 11.9
11 pure autonomic failure 11.8
12 autonomic dysfunction 11.7
13 insensitivity to pain, congenital, with anhidrosis 11.6
14 stuve-wiedemann syndrome 11.3
15 fatal familial insomnia 11.2
16 autonomic nervous system disease 11.1
17 parkinson disease 1, autosomal dominant 11.0
18 neuropathy, hereditary sensory and autonomic, type vi 10.9
19 hereditary sensory neuropathy 10.9
20 rigidity and multifocal seizure syndrome, lethal neonatal 10.8
21 postural hypotension 10.8
22 primary orthostatic hypotension 10.8
23 parkinson disease 23, autosomal recessive early-onset 10.8
24 scoliosis, isolated 1 10.8
25 autoimmune autonomic ganglionopathy 10.8
26 autoimmune gastrointestinal dysmotility 10.8
27 neuropathy 10.2
28 brain injury 10.1
29 traumatic brain injury 10.1
30 parkinson disease 10 10.1 PRKN SNCA
31 parkinson disease 2, autosomal recessive juvenile 10.1 PRKN SNCA
32 neuronitis 10.1
33 early-onset parkinson disease 10.0 PRKN SNCA
34 neuroaxonal dystrophy 10.0 NTRK1 SNCA
35 parkinson disease 15, autosomal recessive early-onset 10.0 PRKN SNCA
36 tremor 10.0 PRKN SNCA
37 polyneuropathy 9.9
38 myopathy 9.8
39 leprosy 3 9.8
40 episodic pain syndrome, familial, 1 9.8
41 syncope 9.8
42 orthostatic intolerance 9.8
43 diabetes mellitus 9.8
44 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
45 essential tremor 9.8 PRKN SNCA
46 migraine with or without aura 1 9.8
47 chronic fatigue syndrome 9.8
48 cerebritis 9.8
49 esophagitis 9.8
50 chagas disease 9.8

Graphical network of the top 20 diseases related to Dysautonomia:



Diseases related to Dysautonomia

Symptoms & Phenotypes for Dysautonomia

GenomeRNAi Phenotypes related to Dysautonomia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased telomerase activity GR00156-A 8.62 ELP1 NTRK1

MGI Mouse Phenotypes related to Dysautonomia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 8.92 ELP1 NTRK1 PRKN SNCA

Drugs & Therapeutics for Dysautonomia

Drugs for Dysautonomia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 495)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 1 51384-51-1, 37350-58-6 4171
3
Acetylcholine Approved Phase 4 51-84-3 187
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Midodrine Approved Phase 4,Phase 3,Phase 2,Phase 1 42794-76-3, 133163-28-7 4195
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Bupivacaine Approved, Investigational Phase 4,Phase 3 38396-39-3, 2180-92-9 2474
8
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
9 Zotepine Approved, Investigational Phase 4 26615-21-4
10
Zolpidem Approved Phase 4 82626-48-0 5732
11
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
12
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
13
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-92-7 6047
14
Propranolol Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 525-66-6 4946
15
Fludrocortisone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 127-31-1 31378
16
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23651-95-8 443940
17
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
18
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 1
19
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
20
Bisoprolol Approved Phase 4 66722-44-9 2405
21
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Early Phase 1 50-81-7 54670067 5785
22 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
24 triamcinolone acetonide Phase 4,Phase 3
25
Serotonin Phase 4,Phase 2,Phase 1,Early Phase 1 50-67-9 5202
26 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
27 Dopamine agonists Phase 4,Phase 1
28 abobotulinumtoxinA Phase 4
29 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Serotonin Agents Phase 4,Phase 2,Phase 1,Early Phase 1
34 Serotonin Antagonists Phase 4
35 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Adrenergic Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
37 Adrenergic beta-1 Receptor Antagonists Phase 4,Phase 2,Phase 1
38 N 0437 Phase 4
39 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
40 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 GABA Agents Phase 4,Early Phase 1
42 GABA Agonists Phase 4
43 GABA-A Receptor Agonists Phase 4
44 Sympatholytics Phase 4,Phase 3,Phase 2,Phase 1
45 Neuromuscular Agents Phase 4
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Triamcinolone diacetate Phase 4,Phase 3
50 Triamcinolone hexacetonide Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 509)

# Name Status NCT ID Phase Drugs
1 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome Unknown status NCT01823770 Phase 4 Rotigotine;Placebo patchs
2 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
3 Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study) Unknown status NCT01621464 Phase 4
4 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
5 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
6 Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
7 Heart Rate Variability in Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
8 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
9 Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
10 Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
11 Prophylactic Administration of Vitamin C in Wrist Fractures Completed NCT00296868 Phase 4 ascorbic acid (vitamin C) versus placebo
12 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study Completed NCT02308124 Phase 4 Midodrine;Pyridostigmine Bromide;Midodrine + pyridostigmine
13 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
14 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4 Midodrine HCl;Placebo
15 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
16 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
17 Clinical Trial for the Prevention of Vasovagal Syncope Completed NCT00118482 Phase 4 fludrocortisone acetate
18 Restore Claims Characterization Study Completed NCT00200122 Phase 4
19 High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System Completed NCT02265848 Phase 4
20 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
21 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
22 Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor Recruiting NCT03178591 Phase 4 vildagliptin;Dapagliflozin
23 Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH Recruiting NCT03350659 Phase 4 Midodrine;Atomoxetine
24 Dawn Simulation and Postural Hypotension Recruiting NCT02632318 Phase 4
25 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
26 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
27 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Active, not recruiting NCT03098368 Phase 4 Rotigotine;Placebo
28 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
29 Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) Active, not recruiting NCT02171988 Phase 4 Propranolol;Bisoprolol;Propranolol+pyridostigmine;Bisoprolol+pyridostgmine
30 Brain Perfusion & Oxygenation in Parkinson's Disease With NOH Not yet recruiting NCT03229174 Phase 4 Droxidopa;Placebo
31 Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome Not yet recruiting NCT03291197 Phase 4 Suprascapular and median nerve blocks
32 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
33 A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients Unknown status NCT01314625 Phase 3
34 Post-Exercise Hypotension in Elderly Hypertensive Men Unknown status NCT02415582 Phase 3
35 Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease Unknown status NCT00629161 Phase 2, Phase 3 Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant);placebo
36 Surgical Treatment Of Complex Regional Pain Syndrome Type II (CRPS II) Unknown status NCT01392599 Phase 3
37 Acupuncture for Post-stroke Shoulder-hand Syndrome Unknown status NCT02011854 Phase 2, Phase 3
38 RCT :Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
39 Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block Unknown status NCT01134289 Phase 3
40 Intravenous Immunoglobulins in Complex-regional Pain Syndrome Unknown status NCT00949065 Phase 3
41 The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia Completed NCT01987219 Phase 3 Albuterol-sulphate;Ipratropium-bromide
42 Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia Completed NCT01212484 Phase 3 Carbidopa;Placebo
43 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
44 The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury Completed NCT02099890 Phase 3
45 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Completed NCT01522235 Phase 2, Phase 3 Double blinded IVIg
46 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) Completed NCT01132326 Phase 3 Droxidopa
47 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
48 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
49 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
50 Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease Completed NCT00656253 Phase 2, Phase 3 Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.);Placebo

Search NIH Clinical Center for Dysautonomia

Genetic Tests for Dysautonomia

Genetic tests related to Dysautonomia:

# Genetic test Affiliating Genes
1 Dysautonomia 28

Anatomical Context for Dysautonomia

MalaCards organs/tissues related to Dysautonomia:

38
Heart, Spinal Cord, Brain, Testes, Liver, Bone, Cortex

Publications for Dysautonomia

Articles related to Dysautonomia:

(show top 50) (show all 617)
# Title Authors Year
1
Neurogenic dysphagia with undigested macaroni and megaesophagus in familial dysautonomia. ( 29196937 )
2018
2
Development of a clinical prediction score for detection of suspected cases of equine grass sickness (dysautonomia) in France. ( 29204821 )
2018
3
Severe dysautonomia as a main feature of anti-GAD encephalitis: Report of a paediatric case and literature review. ( 29370977 )
2018
4
Dysautonomia in the pathogenesis of migraine. ( 29212396 )
2018
5
Ambulatory blood pressure profiles in familial dysautonomia. ( 29435868 )
2018
6
A Controlled Trial of Inhaled Bronchodilators in Familial Dysautonomia. ( 29234869 )
2018
7
Equine Dysautonomia. ( 29398183 )
2018
8
BGP-15 prevents the death of neurons in a mouse model of familial dysautonomia. ( 28439028 )
2017
9
Sudden Unexpected Death During Sleep in Familial Dysautonomia: A Case-Control Study. ( 28521050 )
2017
10
Basic research and model systems in familial dysautonomia: What do we know and what's next? ( 28707017 )
2017
11
Pathological Confirmation of Optic Neuropathy in Familial Dysautonomia. ( 28395083 )
2017
12
Use of Biotronik closed loop pacemaker to treat recurrent syncope in pediatric patient with dysautonomia. ( 28491761 )
2017
13
Methotrexate-induced dysautonomia in a patient with rheumatoid arthritis. ( 28398506 )
2017
14
Animal and cellular models of familial dysautonomia. ( 28667575 )
2017
15
Calming the Storm: Dysautonomia for the Pediatrician. ( 28716515 )
2017
16
<i>IKBKAP/ELP1</i> gene mutations: mechanisms of familial dysautonomia and gene-targeting therapies. ( 29290691 )
2017
17
Alterations in amino acid status in cats with feline dysautonomia. ( 28333983 )
2017
18
Optimising physiology for adolescents with dysautonomia. ( 28477426 )
2017
19
Founder mutation in IKBKAP gene causes vestibular impairment in familial dysautonomia. ( 29289840 )
2017
20
Pure autonomic failure versus prodromal dysautonomia in Parkinsona89s disease: Insights from the bedside. ( 28164144 )
2017
21
Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia. ( 28404519 )
2017
22
Partial dysautonomia: An interesting presentation. ( 28749384 )
2017
23
Intranasal dexmedetomidine for adrenergic crisis in familial dysautonomia. ( 28674865 )
2017
24
Transient dysautonomia in an acute phase of encephalopathy with biphasic seizures and late reduced diffusion. ( 28413125 )
2017
25
Familial dysautonomia: a disease with hidden tears. ( 28401297 )
2017
26
RBM24 promotes U1 snRNP recognition of the mutated 5' splice site in the IKBKAP gene of familial dysautonomia. ( 28592461 )
2017
27
Response Letter to 'Optimising physiology for adolescents with dysautonomia'. ( 28906019 )
2017
28
Ipilimumab-induced Guillain-BarrAc Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy. ( 28452849 )
2017
29
Pyridoxine Toxicity Small Fiber Neuropathy With Dysautonomia: A Case Report. ( 28827489 )
2017
30
Human papilloma virus vaccination and dysautonomia: Considerations for autoantibody evaluation and HLA typing. ( 27553747 )
2016
31
Familial dysautonomia: History, genotype, phenotype and translational research. ( 27317387 )
2016
32
Sensory and autonomic deficits in a new humanized mouse model of familial dysautonomia. ( 26769677 )
2016
33
Dysautonomia in prodromal I+-synucleinopathy: peripheral versus central autonomic degeneration. ( 26842960 )
2016
34
Familial Dysautonomia: Mechanisms and Models. ( 27561110 )
2016
35
MicroRNA screening identifies a link between NOVA1 expression and a low level of IKAP in familial dysautonomia. ( 27483351 )
2016
36
Tocotrienol Treatment in Familial Dysautonomia: Open-Label Pilot Study. ( 27129499 )
2016
37
Psychiatric manifestations and dysautonomia at the onset of focal epilepsy in adults: Clinical signs indicating autoimmune origin. ( 27311973 )
2016
38
Obstructive Sleep Disordered Breathing Is More Common than Central in Mild Familial Dysautonomia. ( 27655467 )
2016
39
Poster 257 Tizanidine Reduces Night Sweats due to Dysautonomia in Syringomyelia: A Case Report. ( 27673012 )
2016
40
Poster 72 Teetering on the Edge: Rehabilitation in a Medically Complex Patient with Familial Dysautonomia (Hereditary Sensory Autonomic Neuropathy Type III): A Case Report. ( 27672840 )
2016
41
Axon Transport and Neuropathy: Relevant Perspectives on the Etiopathogenesis of Familial Dysautonomia. ( 26724390 )
2016
42
Body weight and dysautonomia in early Parkinson's disease. ( 27357472 )
2016
43
Prominent dysautonomia in a patient with POEMS syndrome. ( 27165541 )
2016
44
Dysautonomia Differentially Influences the Effect of Affective Pain Perception on Quality of Life in Parkinson's Disease Patients. ( 27239367 )
2016
45
Cerebral autoregulation and symptoms of orthostatic hypotension in familial dysautonomia. ( 27613312 )
2016
46
Twenty-four-hour blood pressure profile, orthostatic hypotension, and cardiac dysautonomia in elderly type 2 diabetic hypertensive patients. ( 27624333 )
2016
47
Mother-induced hypertension in familial dysautonomia. ( 26589199 )
2016
48
A patient with PMP22-related hereditary neuropathy and DBH-gene-related dysautonomia. ( 26410747 )
2015
49
Lower urinary tract dysfunction in patients with dysautonomia. ( 26530163 )
2015
50
Vertigo with dysautonomia and serious allergy: An unusual case of juvenile MAcniA"re's disease. ( 26442804 )
2015

Variations for Dysautonomia

Expression for Dysautonomia

Search GEO for disease gene expression data for Dysautonomia.

Pathways for Dysautonomia

GO Terms for Dysautonomia

Cellular components related to Dysautonomia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 8.8 NTRK1 SNCA SNCAIP

Biological processes related to Dysautonomia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.63 PRKN SNCA SNCAIP
2 negative regulation of protein phosphorylation GO:0001933 9.51 PRKN SNCA
3 negative regulation of neuron apoptotic process GO:0043524 9.5 NTRK1 PRKN SNCA
4 adult locomotory behavior GO:0008344 9.49 PRKN SNCA
5 protein destabilization GO:0031648 9.48 PRKN SNCA
6 regulation of reactive oxygen species metabolic process GO:2000377 9.43 PRKN SNCA
7 regulation of dopamine secretion GO:0014059 9.4 PRKN SNCA
8 synaptic transmission, dopaminergic GO:0001963 9.37 PRKN SNCA
9 negative regulation of neuron death GO:1901215 9.33 NTRK1 PRKN SNCA
10 dopamine uptake involved in synaptic transmission GO:0051583 9.26 PRKN SNCA
11 regulation of neurotransmitter secretion GO:0046928 9.13 PRKN SNCA SNCAIP
12 dopamine metabolic process GO:0042417 8.8 PRKN SNCA SNCAIP

Molecular functions related to Dysautonomia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase binding GO:0019900 9.16 NTRK1 PRKN
2 Hsp70 protein binding GO:0030544 8.96 PRKN SNCA
3 phospholipase binding GO:0043274 8.62 PRKN SNCA

Sources for Dysautonomia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....